Last updated: February 24, 2026
What Is the Drug with NDC 72888-0066?
NDC 72888-0066 refers to Zepzelca (lurbinectedin), a medication approved in the United States by the Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.[1] It is marketed by Pharma Mar.
Market Overview
Indication and Usage
Lurbinectedin is indicated for relapsed small cell lung cancer (SCLC) with progressive disease following platinum-based chemotherapy. It received accelerated approval in June 2020 and full approval in March 2022, reflecting an increased adoption rate in oncology settings.
Market Size and Growth Drivers
The SCLC market is relatively small, primarily due to the rarity of advanced cases. The global incidence of SCLC is 10-15% of lung cancers, with approximately 250,000 new cases annually worldwide.[2] However, the unmet need for effective second-line therapies sustains demand for drugs like lurbinectedin.
Competitive Landscape
Lurbinectedin faces competition from:
- Topotecan: A standard second-line treatment.
- Lurbinectedin's unique mechanism offers potential advantages over existing options, fostering premium pricing.
- Upcoming therapeutics: Emerging agents and immunotherapies could impact future market share.
Reimbursement and Pricing Dynamics
Reimbursement for lurbinectedin varies. The drug's initial pricing was set at approximately $11,674 per 3.2 mg/vial (the recommended dose), translating to roughly $3,000 per cycle.[3] Insurance coverage is evolving, contingent on payer assessments and value propositions.
Geographic Reach
Initial commercialization targets the U.S. market, with subsequent expansion into Europe and other regions. Regulatory approval timing influences market penetration, expected to grow over the next 3-5 years.
Price Projections
Historical Price Trends
The launch price for lurbinectedin was set at about $11,674 per cycle, a strategic premium relative to topotecan (~$4,500 per course)[4]. Early adoption reflects a focus on combination therapy settings and refractory SCLC.
Projections (2023-2028)
| Year |
Estimated Average Price per Cycle |
Market Penetration |
Revenue Projections (USD millions) |
| 2023 |
$11,674 |
10% of eligible population |
$20-25 |
| 2024 |
$11,674 |
20% |
$40-50 |
| 2025 |
$11,674 |
35% |
$70-80 |
| 2026 |
$11,674 |
50% |
$100-120 |
| 2027 |
$11,674 |
65% |
$140-160 |
| 2028 |
$11,674 |
75% |
$180-200 |
Assumptions: Penetration rates are based on regulatory approval status, clinician adoption, and reimbursement landscape. Price remains relatively stable; however, discounts and rebates could lower net prices by 10-20%.
Factors Impacting Price Trajectory
- Patent and exclusivity status: Exclusivity for patent-protected compounds sustains pricing. Patent expiry anticipated in late 2028.
- Generic entry: Predicted in 2029, potentially halving prices.
- Market competition: New therapies or biosimilars could induce downward pricing pressure.
- Reimbursement negotiations: Payers’ acceptance impacts net pricing and market access.
Key Market Risks and Opportunities
Risks
- Delays in further regulatory approvals.
- Competitive erosion from emerging therapies.
- Reimbursement limitations or adverse pricing pressures.
Opportunities
- Expanding indications (e.g., earlier lines of therapy, other neuroendocrine tumors).
- Combination therapy trials that could broaden usage.
- Price adjustments linked to demonstrated clinical benefits or biosimilar entry.
Summary
NDC 72888-0066 (lurbinectedin) operates within a niche but growing segment characterized by high unmet need. Its current high price is justified by clinical differentiation and limited competition. Market growth hinges on expanded indications, reimbursement, and eventual generic entry.
Key Takeaways
- Lurbinectedin's current pricing is approximately $11,674 per cycle.
- Market size remains modest, with an increasing adoption forecast over the next five years.
- Revenue projections indicate potential for USD 180-200 million annually by 2028.
- Competition and patent expiry are primary influences on long-term pricing.
- Expansion into new indications and geographic markets presents growth opportunities.
FAQs
Q1: When will generic versions of lurbinectedin likely enter the market?
A1: Patent expiration is expected in late 2028, with generics possible starting late 2029, subject to patent challenges and regulatory processes.
Q2: How does the price of lurbinectedin compare to similar therapies?
A2: It is priced higher than standard second-line therapies, reflecting its novel mechanism and clinical benefits. For example, topotecan costs around $4,500 per course.
Q3: What factors could influence the reduction of net price?
A3: Payer negotiations, volume discounts, rebates, and eventual biosimilar entry.
Q4: Are there ongoing trials to expand lurbinectedin's indications?
A4: Yes, trials are ongoing for combination therapies and other tumor types, which could lead to broader use.
Q5: What is the forecasted impact of biosimilar entry?
A5: Likely significant price reductions, potentially halving existing prices within 2-3 years after entry.
References
- FDA. (2020). FDA grants accelerated approval to lurbinectedin for small cell lung cancer.
- Siegel, R. L., et al. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7-33.
- Pharma Mar. (2020). Lurbinectedin prescribing information.
- IQVIA. (2021). Oncology drug pricing benchmarks.
